Author

C. E. Bond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:diffusion model· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

J. Borowsky· 2 shared L. J. Fennell· 2 shared V. L. Whitehall· 2 shared A. Kane· 1 shared A. M. Kane· 1 shared B. A. Leggett· 1 shared B. Leggett· 1 shared B. Salik· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Borowsky

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Attenuation of the CpG Island Methylator Phenotype and lack of WNT signaling activation restrains Kras mutant intestinal neoplasia

L. J. Fennell, S. Tria, C. Liu, A. Kane, D. McKeone, J. Borowsky, L. Chai, S. Randall-demllo, C. E. Bond, B. Leggett, V. L. Whitehall

This study compares Kras and Braf mutant intestinal neoplasia in mice, showing Kras mutations lead to less aggressive serrated lesions with reduced WNT signaling activation and attenuated DNA methylation changes compared to Braf mutations.

bioRxiv · Dec 21, 2023 · PreprintCancer Biology

Aspirin synergizes with regorafenib to reduce growth of colorectal cancer

C. Su, L. J. Fennell, C. E. Bond, A. M. Kane, G. Kerr, T. Jarde, D. Micati, R. M. Engel, W. H. Chan, S. Hlavca, S. Archer, P. J. McMurrick, H. Hammerlindl, F. Lim, B. Salik, , V. L. Whitehall

This study shows that aspirin and regorafenib together reduce colorectal cancer growth in preclinical models by inhibiting the PI3K-Akt-mTOR pathway and activating AMPK.

bioRxiv · Feb 11, 2022 · PreprintCancer Biology